Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials

Heier J.; Khanani A.; Ruiz Carlos Quezada; Basu K.; Ferrone P.; Brittain C.; Figueroa M.; Lin Hugh; Holz F.; Patel V.; Lai T.; Silverman David; Regillo C.; Swaminathan Balakumar; Viola F.; Cheung C.; Wong T.; Abbey A.; Abdulaeva E.B.K; Abraham P.; Civera A. A.; Agostini H.; Alezzandrini A.; Alfaro Virgil; Almony A.; Altay L.; Amini Payam; Antoszyk A.; Aradi Etelka; Arias L.; Arnold J.; Asaria R.; Astakhov S.; Astakhov Y.; Awh C.; Balaratnasingam Chandrakumar; Banerjee Sanjiv; Baumal C.; Becker M.; Belfort Rubens; Bratko Galina; Bridges William; Brown Jamin S.; Brown David M.; Budzinskaya M.; Buffet S.; Burgess S.; Byon I.; Cagini C.; Calzada J.; Cameron S.; Campochiaro P.; Carlson John; Carneiro Â.; Chan C.; Chang E.; Chang Andrew; Chao D.; Chaudhry N.; Chee C.; Cheek A.; Chen S.; Chen San-Ni; Cheung Gemmy C M; Chexal Saradha; Chittum M.; Chow David; Cole Abosede; Connolly B.; Cornut P.; Couvillion Steven C.; Danzig Carl J.; Daskalov Vesselin; Dessouki A.; Devin F.; Dollin Michael L; Dolz R.; Downey L.; Dreyer R.; Dugel P.; Eichenbaum David A.; Eldem B.; Engstrom R.; Escobar J.; Eter N.; Faber D.; Falk N.; Feiner L.; Vega Alvaro Fernandez; Ferrone P.; Figueroa Marta; Fine Howard I.; Fineman Mitchell; Fox G. M.; Français C.; Franco Pablo; Fraser-bell S.; Fung Nicholas S. K.; Sola F.; Gale R.; García-Layana A.; Gasperini J.; Gawęcki Maciej; Ghanchi F.; Gill M.; Giunta M.; Glaser D.; Goldstein Michael B.; Ulla Francisco Gomez; Gomi F.; González Víctor; Graff J.; Gupta Sunil; Guthoff R.; Guymer R.; Haas A.; Hampton Robert; Hatz K.; Hayashi Ken; Heier J.; Herba E.; Hershberger Vrinda S.; Higgins Patrick; Holekamp N.; Honda S.; Howard James; Hu Allen; Huddleston Stephen M; Iida T.; Imaizumi H.; Ito Yasuo; Ito Yasuki; Itty S.; Javey G.; Javid Cameron G.; Kaga T.; Kałużny J.; Kang S.; Kapoor K.; Karabaş L.; Kawasaki Tsutomu; Kelty Patrick J.; Kerényi Á.; Khanani A.; Khoramnia R.; Khurana R.; Kimura Kazuhiro; Klein-Mascia Kendra; Kobayashi Namie; Kodjikian L.; Koizumi H.; Kokame G.; Kulikov A.; Kwong Henry; Kwun R.; Lai T.; Lai Chi-Chun; Lalonde L.; Lanzetta P.; Larsen M.; Lavina A.; Lee W.; Lee Ji Eun; Lee Seong-Cheol; Levy J.; Lindsell Luke B; Liu Mimi; London N.; Lotery A.; Rechy D. L.; Luckie A.; Maberley D.; Maeno T.; Mahmood S.; Makkouk Fuad; Marcus D.; Margherio Alan R.; Massé H.; Matsubara Hisashi; Maturi R.; Mehta S.; Menon G.; Menteş J.; Michels M.; Mitamura Y.; Mitchell Paul; Mohamed Q.; Monés J.; Lobo Rodrigo Montemayor; Montero J.; Moore Jeffrey; Mori R.; Morori-Katz Haia; Mukherjee R.; Murata T.; Muzyka-Woźniak M.; Nardi M.; Narendran N.; Nicolò M.; Nielsen J.; Nishimura T.; Noda K.; Nowinska A.; Oh H.; Ohr Matthew P.; Okada A.; Oleksy P.; Ono S.; Ozdek S.; Ozturk B.; Pablo L.; Park K.; Parke D.; Parravano M.; Patel P.; Patel Apurva; Patel Sunil S.; Patel Sugat S; Pauleikhoff D.; Pearce I.; Pearlman J.; Petkova I.; Pieramici D.; Pozdeyeva N.; Qureshi J.; Raczyńska D.; Estudillo J.; Rathod R.; Razavi H.; Reilly Gayatri S.; Ricci F.; Rich R.; Romanowska-Dixon B.; Rosenblatt I.; Moreno J.; Sacu S.; Saedon H.; Saeed Usman; Sagong M.; Sakamoto T.; Sandhu S.; Sararols L.; Saravia M.; Schadlu Ramin; Schlottmann P.; Sekiryu T.; Seres A.; Şermet F.; Shah Sumit P.; Shah Rohan; Shah Ankur; Sheidow T.; Sheth V.; Shiragami C.; Sikorski B.; Silva Rufino; Singerman L.; Sisk R.; Sørensen T.; Souied E.; Spinak D.; Staurenghi G.; Steinmetz R.; Stoller G.; Stoltz R.; Suan Eric P; Suñer I.; Suzanne Y.; Tadayoni R.; Takahashi Kanji; Takayama K.; Taleb A.; Talks J.; Terasaki H.; Thompson J.; Tóth-Molnár E.; Tran Khoi D.; Tuli R.; Uchiyama E.; Vajas A.; Lith-Verhoeven Janneke Van; Varsányi B.; Virgili G.; Vogt G.; Völker M.; Warrow David J.; Weber Pamela; Wells J.; Wickremasinghe S.; Wieland M.; Williams Geoff; Williams Thomas; Wong D.; Wong King; Wong James; Wong I.; Wong Robert; Wowra B.; Wykoff C.; Yamashita Ayana; Yasuda K.; Yılmaz G.; Yiu Glenn; Yoneda Ai; Yoon Y.; Yoreh Barak; Yu HyeongGon; Yu Seung-Young; Yurieva Tatiana S.; Zambrano A.; Zatorska B.; Zeolite Carlos

doi:10.1016/s0140-6736(22)00010-1

← Today's brief

Study

Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials

Heier J. et al. · Lancet · Saturday, January 1, 2022

Read original

Funding Not reported

Source

Heier J. et al.. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials. Lancet. Saturday, January 1, 2022.
doi:10.1016/s0140-6736(22)00010-1

Generated, then checked claim-by-claim against the source · how this brief was built →

Physician-designed methodology · Amr Saad, MD MBA

Sign in to rate and bookmark articles

Automated evidence summary, checked against the source. Not medical advice. Verify with the original publication.